Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus PROMETHAZINE W DEXTROMETHORPHAN.
Head-to-head clinical analysis: CHILDREN S FEXOFENADINE HYDROCHLORIDE HIVES versus PROMETHAZINE W DEXTROMETHORPHAN.
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES vs PROMETHAZINE W/ DEXTROMETHORPHAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a peripheral H1-receptor antagonist that selectively inhibits histamine-mediated effects on H1 receptors, reducing allergic symptoms. It does not penetrate the blood-brain barrier significantly, minimizing sedation.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist and antiemetic; dextromethorphan is a non-opioid antitussive that acts as an NMDA receptor antagonist and sigma-1 receptor agonist.
Adults and children 12 years and older: 180 mg orally once daily or 60 mg orally twice daily.
5 mL (containing promethazine 6.25 mg and dextromethorphan 15 mg) orally every 4-6 hours as needed, not to exceed 30 mL (promethazine 37.5 mg, dextromethorphan 90 mg) per 24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 14.4 hours (range 11–15 hours) in healthy adults. This supports once-daily dosing. Half-life may be prolonged in patients with renal impairment (up to 19 hours).
Promethazine: 9-16 h; dextromethorphan: 3-5 h (extensive metabolizers), 30-50 h (poor metabolizers). Clinical context: dosing interval typically 4-6 h for dextromethorphan; promethazine accumulates with repeated dosing.
Fexofenadine is primarily excreted unchanged in feces (approximately 80%) via biliary elimination, with minimal renal excretion (approximately 11%). It is not metabolized by the liver.
Renal: promethazine ~6% unchanged, dextromethorphan ~0.5% unchanged; metabolites primarily renal. Biliary/fecal: minor routes for both.
Category A/B
Category A/B
Antihistamine
Antihistamine / Antiemetic